Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis to globally co-commercialise Amgen’s migraine drug

europeanpharmaceuticalreviewMay 07, 2019

Tag: AMG 334 , erenumab , Novartis , Amgen , Migraine

PharmaSources Customer Service